Trial Profile
PRIMARY PREVENTION OF HEPATOCELLULAR CARCINOMA BY METFORMIN IN PATIENTS WITH VIRAL C CIRRHOSIS : PROSPECTIVE MULTICENTER STUDY, RANDOMIZED CONTROL TRIAL. Ancillary Study of the ANRS CO12 CirVir Cohort
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2021
Price :
$35
*
At a glance
- Drugs Metformin (Primary)
- Indications Liver cancer; Liver cirrhosis
- Focus Therapeutic Use
- Acronyms METFOVIR
- 10 Jan 2017 Status changed from recruiting to discontinued. Reason behind this is the Decision of investigator.
- 09 May 2016 Planned End Date changed from 1 Dec 2020 to 1 Jun 2021.
- 09 May 2016 Planned primary completion date changed from 1 Dec 2018 to 1 Jun 2019.